[Present and future in development of new anti-influenza drugs].
Against pandemic influenza A (H1N1) 2009, anti-influenza drugs were useful to save the disease aggravation and reduce the mortality. In addition to the existing anti-influenza drugs, novel drugs, including neuraminidase inhibitors (peramivir and laninamivir) and RNA polymerase inhibitors (favipiravir), also have clinical potentials to suppress pandemic influenza A (H1N1) 2009 virus as well as seasonal influenza virus.
Watanabe
Akira
A
Research Division for Development of Anti-Infective Agents, Institute of Development, Aging and Cancer, Tohoku University.
D000547:Amantadine / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy*; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D053139:Oseltamivir / Q000494:pharmacology; D053243:Zanamivir / Q000494:pharmacology
D000998:Antiviral Agents; D004791:Enzyme Inhibitors; D053139:Oseltamivir; D000547:Amantadine; D012321:DNA-Directed RNA Polymerases; D009439:Neuraminidase; D053243:Zanamivir